C R Bard Inc (BCR) was Upgraded by Wells Fargo to ” Outperform”. Earlier the firm had a rating of “Market Perform ” on the company shares. Wells Fargo advised their investors in a research report released on Sep 16, 2016.
Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
C R Bard Inc opened for trading at $213.34 and hit $217.36 on the upside on Wednesday, eventually ending the session at $216.91, with a gain of 1.83% or 3.89 points. The heightened volatility saw the trading volume jump to 651,788 shares. Company has a market cap of $15,933 M.
In a different news, on Sep 8, 2016, Samrat S. Khichi (Sr. VP, Gen Counsel & Secy.) sold 9,183 shares at $221.21 per share price. According to the SEC, on Sep 8, 2016, John A Deford (Sr. VP Sci Tech and Clin Afrs) sold 7,928 shares at $221.30 per share price. On Jun 1, 2016, Christopher S Holland (Senior Vice President and CFO) sold 3,970 shares at $219.88 per share price, according to the Form-4 filing with the securities and exchange commission.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.